DNA甲基化与宫颈癌临床应用趋势与挑战  

The trend and challenge of DNA methylation clinical application in cervical cancer

作　　者：刘禹利 谢小兵[2] 陈飞[3] 楼伟珍[3] 米玛[4] 李芳 Liu Yuli;Xie Xiaobing;Chen Fei;Lou Weizhen;Mi Ma;Li Fang(Precision Medicine Center,the First Affiliated Hospital of Guangdong Pharmaceutical University,Guangzhou 510000,China;Medical Laboratory and Pathology Center,the First Affiliated Hospital of Hunan University of Traditional Chinese Medicine,Changsha 410007,China;National Clinical Research Center for Obstetric&Gynecologic Diseases,Department of Obstetrics and Gynecology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100730,China;Department of Gynecology,People′s Hospital of Tibet Autonomous Region,Lhasa 850000,China)

机构地区：[1]广东药科大学附属第一医院精准医学中心,广州510000 [2]湖南中医药大学第一附属医院医学检验与病理中心,长沙410007 [3]国家妇产疾病临床医学研究中心,中国医学科学院北京协和医学院北京协和医院妇产科,北京100730 [4]西藏自治区人民医院妇科,拉萨850000

出　　处：《中华检验医学杂志》2023年第4期341-346,共6页Chinese Journal of Laboratory Medicine

基　　金：中国医学科学院基金(2022-PUMCH-D-003);西藏自治区自然科学基金(XZ2022ZR-ZY06(Z))。

摘　　要：依据现行宫颈癌筛查策略与世界卫生组织宫颈癌筛查指南,未来会考虑将基因甲基化纳入新的指南。然而,关于DNA甲基化检测在宫颈癌的具体临床应用价值还有待讨论。本文回顾了DNA甲基化在宫颈癌发生过程中的作用,并讨论了甲基化检测在高危型人乳头瘤病毒(hrHPV)阳性女性管理中的潜在临床应用。认为甲基化检测不仅可用于hrHPV阳性女性的初步分流;还可用于轻微细胞学异常女性的二级分流,以确定宫颈上皮内瘤变3级(CIN3)或癌的高风险;同时也可用于即将终止宫颈癌筛查规划者的辅助检测,为CIN的管理提供支持。According to the current cervical cancer screening strategy and the World Health Orgnization cervical cancer diagnosis/screening guidelines,gene methylation will be included in the new guidelines in the future.However,the value of detecting DNA methylation at specific sites in the clinical specimens during the cervical cancer treatment remains to be discussed.This article summarised the role of DNA methylation in the development of cervical cancer and discusses the potential clinical application of methylation detection in the management of high-risk human papillomavirus(hrHPV)positive female patients.It is believed that methylation test can not only be used for the preliminary classification of hrHPV positive female patients,but also for the secondary triage of female patients with slight cytological abnormalities to determine the high risk of cervical intraepithelial neoplasia 3(CIN3)or cancer.It can also be used for the withdrawal test of women in the screening program to support the management of CIN.

关 键 词：宫颈肿瘤 癌症早筛 甲基化 宫颈上皮内瘤变 普查 

分 类 号：R737.33[医药卫生—肿瘤]